Closed at 2.21. What a complete farking dumb gdmf-ing sucker I was to chase at that price (2500 x 2.92). But, for reasons I cannot explain, had I done nothing with it but watch, then it would've probably blown off today and closed well north of 3. Way this stuff goes.
No positions anywhere...........got to recuperate and lick wounds for a few days. Almost everything I made shorting SP 500 on Friday was vaporized today with this gd QTWW.
QTWW just got torn to pieces today on HUGE volume. Its chart got completely annihilated by the manipulators today. They wanted it down, and they took it down. Anyone in their way (like my sorry ass)..................
Closed at 2.21. What a complete farking dumb gdmf-ing sucker I was to chase at that price (2500 x 2.92). But, for reasons I cannot explain, had I done nothing with it but watch, then it would've probably blown off today and closed well north of 3. Way this stuff goes.
No positions anywhere...........got to recuperate and lick wounds for a few days. Almost everything I made shorting SP 500 on Friday was vaporized today with this gd QTWW.
QTWW just got torn to pieces today on HUGE volume. Its chart got completely annihilated by the manipulators today. They wanted it down, and they took it down. Anyone in their way (like my sorry ass)..................
The Company announced that data from the 220-patient prospective, randomized pivotal clinical trial of its PAS-Port(R) Proximal Anastomosis System will be presented at the 2008 Annual Scientific Meeting of the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) in Boston. The presentation, entitled "The Cardica PAS-Port Proximal Anastomotic Connector Device: First Report of the Results of the FDA Trial," will be given during the Late Breaking News session on Thursday, June 12, at 1:15 p.m. Eastern Time by principal study investigator John D. Puskas, M.D., chief of cardiac surgery at Emory Crawford Long Hospital in Atlanta. As previously announced, the trial, which compared graft vessel connections made using the PAS-Port system to conventional hand-sewn sutures during CABG procedures, achieved all of its primary and secondary endpoints. Based on the positive trial data, Cardica submitted a 510(k) premarket notification in April to the U.S. Food and Drug Administration for the PAS-Port system.
Panelists for the investor event will include: -- Husam H. Balkhy, M.D., chairman of cardiothoracic surgery at The Wisconsin Heart Hospital and clinical assistant professor of surgery at the Medical College of Wisconsin. He is a well-known advocate of minimally-invasive cardiac surgery and has the largest experience in the United States with distal anastomotic devices in coronary artery bypass. -- Robert S. Poston, M.D., chief of cardiac surgery at Boston Medical Center. Previously, he was an associate professor of surgery at the University of Maryland where he focused his activities in the field of off-pump and minimally-invasive/robotic CABG. His research into minimally-invasive CABG and the hybrid procedure was recognized in 2005 by the Daily Record magazine as an "Innovation of the Year." -- Sudhir Srivastava, M.D., director of robotic and minimally-invasive cardiac surgery at the University of Chicago Medical Center. He pioneered both the da Vinci revascularization and port-only coronary artery bypass surgical methods and has performed more of these procedures than any other surgeon in the world.Webcast Details
The event will be webcast live on Thursday, June 12, at 5:15 p.m. Eastern Time. To access the live and subsequently archived webcast of the discussion, go to the Investor Relations section of Cardica's website at https://www.cardica.com. Please connect to the website at least 15 minutes prior to the webcast to allow for any necessary software downloads.
My guess is that people started digging, and good news got leaked. and short sellers got squeezed, to boot
The Company announced that data from the 220-patient prospective, randomized pivotal clinical trial of its PAS-Port(R) Proximal Anastomosis System will be presented at the 2008 Annual Scientific Meeting of the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) in Boston. The presentation, entitled "The Cardica PAS-Port Proximal Anastomotic Connector Device: First Report of the Results of the FDA Trial," will be given during the Late Breaking News session on Thursday, June 12, at 1:15 p.m. Eastern Time by principal study investigator John D. Puskas, M.D., chief of cardiac surgery at Emory Crawford Long Hospital in Atlanta. As previously announced, the trial, which compared graft vessel connections made using the PAS-Port system to conventional hand-sewn sutures during CABG procedures, achieved all of its primary and secondary endpoints. Based on the positive trial data, Cardica submitted a 510(k) premarket notification in April to the U.S. Food and Drug Administration for the PAS-Port system.
Panelists for the investor event will include: -- Husam H. Balkhy, M.D., chairman of cardiothoracic surgery at The Wisconsin Heart Hospital and clinical assistant professor of surgery at the Medical College of Wisconsin. He is a well-known advocate of minimally-invasive cardiac surgery and has the largest experience in the United States with distal anastomotic devices in coronary artery bypass. -- Robert S. Poston, M.D., chief of cardiac surgery at Boston Medical Center. Previously, he was an associate professor of surgery at the University of Maryland where he focused his activities in the field of off-pump and minimally-invasive/robotic CABG. His research into minimally-invasive CABG and the hybrid procedure was recognized in 2005 by the Daily Record magazine as an "Innovation of the Year." -- Sudhir Srivastava, M.D., director of robotic and minimally-invasive cardiac surgery at the University of Chicago Medical Center. He pioneered both the da Vinci revascularization and port-only coronary artery bypass surgical methods and has performed more of these procedures than any other surgeon in the world.Webcast Details
The event will be webcast live on Thursday, June 12, at 5:15 p.m. Eastern Time. To access the live and subsequently archived webcast of the discussion, go to the Investor Relations section of Cardica's website at https://www.cardica.com. Please connect to the website at least 15 minutes prior to the webcast to allow for any necessary software downloads.
My guess is that people started digging, and good news got leaked. and short sellers got squeezed, to boot
If you choose to make use of any information on this website including online sports betting services from any websites that may be featured on this website, we strongly recommend that you carefully check your local laws before doing so.It is your sole responsibility to understand your local laws and observe them strictly.Covers does not provide any advice or guidance as to the legality of online sports betting or other online gambling activities within your jurisdiction and you are responsible for complying with laws that are applicable to you in your relevant locality.Covers disclaims all liability associated with your use of this website and use of any information contained on it.As a condition of using this website, you agree to hold the owner of this website harmless from any claims arising from your use of any services on any third party website that may be featured by Covers.